World-class Performance with Assistance of Artificial Intelligence

STOCKHOLM, Dec. 12, 2019 /PRNewswire/ — In the latest version of Ortoma Treatment Solution, OTS 4, Ortoma has introduced support of Artificial Intelligence. The system drastically reduces the time needed for pre-operatively planning of a hip implant in 3D, which has created a big interest for the company’s unique solution. 

Performance has been a focus area during the development of the latest version of Ortoma Treatment Solution (OTS). With OTS 4, an automatic AI-analysis, which forms the basis for the pre-operative planning, is made. The analysis does not take more than about 30 seconds and includes a suggestion for suitable implant and its optimized position. The surgeon can adjust and verify the result in a simple and intuitive workflow, which only takes a few minutes. This can be compared to other systems, which can take up to 30 minutes to perform the same process.

Linus Byström, CEO, comments: “The upgrade of OTS with support of AI exceeds our high ambitions. A pre-operative planning in 3D can now be done substantially quicker than before. It contributes to consistent and optimal result of the treatment outcome.”

OTS 4 with support of AI is CE marked for the European market, and surgeries where the system was used have been performed in Sweden. The company is planning to file an application for marketing approval in USA and selected markets in Asia. Prioritization between countries is on-going.

Ortoma Treatment Solution™ – careful planning and precise surgery.

For more information, please contact:
Ortomas CEO Linus Byström or Chairman of the board Gunnar Németh
mail: info@ortoma.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/ortoma/r/world-class-performance-with-assistance-of-artificial-intelligence,c2988427

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/world-class-performance-with-assistance-of-artificial-intelligence-300973810.html

SOURCE Ortoma

Staff

Recent Posts

NervGen Pharma Announces Proposed Amendment to Warrants

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB:…

4 hours ago

MyndTec Inc. Completes Ninth Tranche of Non-Brokered Private Placement

Mississauga, Ontario--(Newsfile Corp. - December 12, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"),…

6 hours ago

Dominari Holdings Announces Change of Record Date and Payment Date for $10 Million Cash Dividend

NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) is pleased to announce…

6 hours ago

ISHI Health Launches Virtual Heart Failure Clinics in California and Arizona

SAN DIEGO, Dec. 12, 2025 /PRNewswire/ -- ISHI Health, an innovator in AI-enabled virtual cardiac…

6 hours ago

Zealthy Review 2026: How Zealthy Compares to FitRx and RoenRx for Weight Loss & GLP-1 Care

LOS ANGELES, CA / ACCESS Newswire / December 12, 2025 / The landscape of weight…

6 hours ago

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

ESTERO, FL / ACCESS Newswire / December 12, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP)…

6 hours ago